Regina I Jakacki1, Kenneth J Cohen1, Allen Buxton1, Mark D Krailo1, Peter C Burger1, Marc K Rosenblum1, Daniel J Brat1, Ronald L Hamilton1, Sandrah P Eckel1, Tianni Zhou1, Robert S Lavey1, Ian F Pollack2. 1. Departments of Pediatrics (R.I.J.), Pathology (R.L.H.) and Neurosurgery (I.F.P.), University of Pittsburgh School of Medicine, Pittsburgh, PA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland (K.J.C.); Children's Oncology Group, Operations Office, Monrovia, California (A.B., M.D.K.); Department of Preventive Medicine, University of Southern California, Los Angeles, California (M.D.K, S.P.E.); Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland (P.C.B.); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York (M.K.R.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (D.J.B.); Department of Mathematics and Statistics, California State University, Long Beach, California (T.Z.); Maurer Family Cancer Care Center, Bowling Green, Ohio (R.S.L.). 2. Departments of Pediatrics (R.I.J.), Pathology (R.L.H.) and Neurosurgery (I.F.P.), University of Pittsburgh School of Medicine, Pittsburgh, PA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland (K.J.C.); Children's Oncology Group, Operations Office, Monrovia, California (A.B., M.D.K.); Department of Preventive Medicine, University of Southern California, Los Angeles, California (M.D.K, S.P.E.); Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland (P.C.B.); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York (M.K.R.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (D.J.B.); Department of Mathematics and Statistics, California State University, Long Beach, California (T.Z.); Maurer Family Cancer Care Center, Bowling Green, Ohio (R.S.L.) ian.pollack@chp.edu.
Abstract
BACKGROUND: The prognosis for children with malignant glioma is poor. This study was designed to determine whether lomustine and temozolomide following radiotherapy and concurrent temozolomide improves event-free survival (EFS) compared with historical controls with anaplastic astrocytoma (AA) or glioblastoma (GBM) and whether survival is influenced by the expression of O6-methylguanine-DNA-methyltransferase (MGMT). METHODS: Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide. Adjuvant chemotherapy consisted of up to 6 cycles of lomustine 90 mg/m(2) on day 1 and temozolomide 160 mg/m(2)/day ×5 every 6 weeks. RESULTS: Among the 108 eligible patients with AA or GBM, 1-year EFS was 0.49 (95% CI, 0.39-0.58), similar to the original CCG-945-based design model. However, EFS and OS were significantly improved in ACNS0423 compared with the 86 AA or GBM participants treated with adjuvant temozolomide alone in the recent ACNS0126 study (1-sided log-rank P = .019 and .019, respectively). For example, 3-year EFS was 0.22 (95% CI, 0.14-0.30) in ACNS0423 compared with 0.11 (95% CI, 0.05-0.18) in ACNS0126. Stratifying the comparison by resection extent, the addition of lomustine resulted in significantly better EFS and OS in participants without gross-total resection (P = .019 and .00085 respectively). The difference in EFS and OS was most pronounced for participants with GBM (P = .059 and 0.051, respectively), and those with MGMT overexpression (P = .00036 and .00038, respectively). CONCLUSION: The addition of lomustine to temozolomide as adjuvant therapy in ACNS0423 was associated with significantly improved outcome compared with the preceding COG ACNS0126 HGG study in which participants received temozolomide alone.
BACKGROUND: The prognosis for children with malignant glioma is poor. This study was designed to determine whether lomustine and temozolomide following radiotherapy and concurrent temozolomide improves event-free survival (EFS) compared with historical controls with anaplastic astrocytoma (AA) or glioblastoma (GBM) and whether survival is influenced by the expression of O6-methylguanine-DNA-methyltransferase (MGMT). METHODS: Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide. Adjuvant chemotherapy consisted of up to 6 cycles of lomustine 90 mg/m(2) on day 1 and temozolomide 160 mg/m(2)/day ×5 every 6 weeks. RESULTS: Among the 108 eligible patients with AA or GBM, 1-year EFS was 0.49 (95% CI, 0.39-0.58), similar to the original CCG-945-based design model. However, EFS and OS were significantly improved in ACNS0423 compared with the 86 AA or GBM participants treated with adjuvant temozolomide alone in the recent ACNS0126 study (1-sided log-rank P = .019 and .019, respectively). For example, 3-year EFS was 0.22 (95% CI, 0.14-0.30) in ACNS0423 compared with 0.11 (95% CI, 0.05-0.18) in ACNS0126. Stratifying the comparison by resection extent, the addition of lomustine resulted in significantly better EFS and OS in participants without gross-total resection (P = .019 and .00085 respectively). The difference in EFS and OS was most pronounced for participants with GBM (P = .059 and 0.051, respectively), and those with MGMT overexpression (P = .00036 and .00038, respectively). CONCLUSION: The addition of lomustine to temozolomide as adjuvant therapy in ACNS0423 was associated with significantly improved outcome compared with the preceding COG ACNS0126 HGG study in which participants received temozolomide alone.
Authors: Ian F Pollack; Ronald L Hamilton; Robert W Sobol; Marina N Nikiforova; Maureen A Lyons-Weiler; William A LaFramboise; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Emiko J Holmes; Tianni Zhou; Regina I Jakacki Journal: Childs Nerv Syst Date: 2010-08-20 Impact factor: 1.475
Authors: Kenneth J Cohen; Ian F Pollack; Tianni Zhou; Allen Buxton; Emiko J Holmes; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Ronald L Hamilton; Robert S Lavey; Richard L Heideman Journal: Neuro Oncol Date: 2011-03 Impact factor: 12.300
Authors: R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond Journal: J Neurooncol Date: 1989-07 Impact factor: 4.130
Authors: Martin Glas; Caroline Happold; Johannes Rieger; Dorothee Wiewrodt; Oliver Bähr; Joachim P Steinbach; Wolfgang Wick; Rolf-Dieter Kortmann; Guido Reifenberger; Michael Weller; Ulrich Herrlinger Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544
Authors: Andrey Korshunov; Marina Ryzhova; Volker Hovestadt; Sebastian Bender; Dominik Sturm; David Capper; Jochen Meyer; Daniel Schrimpf; Marcel Kool; Paul A Northcott; Olga Zheludkova; Till Milde; Olaf Witt; Andreas E Kulozik; Guido Reifenberger; Nada Jabado; Arie Perry; Peter Lichter; Andreas von Deimling; Stefan M Pfister; David T W Jones Journal: Acta Neuropathol Date: 2015-03-10 Impact factor: 17.088
Authors: M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike Journal: N Engl J Med Date: 1980-12-04 Impact factor: 91.245
Authors: Regina I Jakacki; Allan Yates; Susan M Blaney; Tianni Zhou; Robert Timmerman; Ashish M Ingle; Lynda Flom; Michael D Prados; Peter C Adamson; Ian F Pollack Journal: Neuro Oncol Date: 2008-05-22 Impact factor: 12.300
Authors: Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert Journal: J Clin Oncol Date: 2008-09-01 Impact factor: 44.544
Authors: Christopher S Hong; Juan C Vasquez; Adam J Kundishora; Aladine A Elsamadicy; Jason M Beckta; Amrita Sule; Asher M Marks; Nalin Leelatian; Anita Huttner; Ranjit S Bindra; Michael L DiLuna; Kristopher T Kahle; E Zeynep Erson-Omay Journal: NPJ Genom Med Date: 2020-06-01 Impact factor: 8.617
Authors: Mark W Kieran; Liliana Goumnerova; Peter Manley; Susan N Chi; Karen J Marcus; Andrea G Manzanera; Maria Lucia Silva Polanco; Brian W Guzik; Estuardo Aguilar-Cordova; C Marcela Diaz-Montero; Arthur J DiPatri; Tadanori Tomita; Rishi Lulla; Lianne Greenspan; Laura K Aguilar; Stewart Goldman Journal: Neuro Oncol Date: 2019-03-18 Impact factor: 12.300
Authors: Gregory K Friedman; James M Johnston; Asim K Bag; Joshua D Bernstock; Rong Li; Inmaculada Aban; Kara Kachurak; Li Nan; Kyung-Don Kang; Stacie Totsch; Charles Schlappi; Allison M Martin; Devang Pastakia; Rene McNall-Knapp; Sameer Farouk Sait; Yasmin Khakoo; Matthias A Karajannis; Karina Woodling; Joshua D Palmer; Diana S Osorio; Jeffrey Leonard; Mohamed S Abdelbaki; Avi Madan-Swain; T Prescott Atkinson; Richard J Whitley; John B Fiveash; James M Markert; G Yancey Gillespie Journal: N Engl J Med Date: 2021-04-10 Impact factor: 91.245
Authors: Margaret E Macy; Mark W Kieran; Susan N Chi; Kenneth J Cohen; Tobey J MacDonald; Amy A Smith; Michael M Etzl; Michele C Kuei; Andrew M Donson; Lia Gore; Jennifer DiRenzo; Tanya M Trippett; Irina Ostrovnaya; Aru Narendran; Nicholas K Foreman; Ira J Dunkel Journal: Pediatr Blood Cancer Date: 2017-05-24 Impact factor: 3.167
Authors: Liana Nobre; Michal Zapotocky; Vijay Ramaswamy; Scott Ryall; Julie Bennett; Daniel Alderete; Julia Balaguer Guill; Lorena Baroni; Ute Bartels; Abhishek Bavle; Miriam Bornhorst; Daniel R Boue; Adela Canete; Murali Chintagumpala; Scott L Coven; Ofelia Cruz; Sonika Dahiya; Peter Dirks; Ira J Dunkel; David Eisenstat; Cecile Faure Conter; Elizabeth Finch; Jonathan L Finlay; Didier Frappaz; Maria Luisa Garre; Karen Gauvain; Anne Grete Bechensteen; Jordan R Hansford; Inga Harting; Peter Hauser; Lili-Naz Hazrati; Annie Huang; Sarah G Injac; Valentina Iurilli; Matthias Karajannis; Gurcharanjeet Kaur; Martin Kyncl; Lenka Krskova; Normand Laperriere; Valerie Larouche; Alvaro Lassaletta; Sarah Leary; Frank Lin; Samantha Mascelli; Tara McKeown; Till Milde; Andres Morales La Madrid; Giovanni Morana; Helena Morse; Naureen Mushtaq; Diana S Osorio; Roger Packer; Zdenek Pavelka; Eduardo Quiroga-Cantero; James Rutka; Magnus Sabel; Duarte Salgado; Palma Solano; Jaroslav Sterba; Jack Su; David Sumerauer; Michael D Taylor; Helen Toledano; Derek S Tsang; Mariana Valente Fernandes; Frank van Landeghem; Cornelis M van Tilburg; Bev Wilson; Olaf Witt; Josef Zamecnik; Eric Bouffet; Cynthia Hawkins; Uri Tabori Journal: JCO Precis Oncol Date: 2020-05-20